Brief: Matinas Biopharma Completes Enrollment Of ENHANCE-IT Study Of MAT9001 Against Vascepa
27/08/2020 21:47
Aug 27 (Reuters) - Matinas BioPharma Holdings Inc MTNB.A :
* MATINAS BIOPHARMA COMPLETES ENROLLMENT OF ENHANCE-IT STUDY
OF
MAT9001 AGAINST VASCEPA®
* EXPECTS TO HAVE TOPLINE DATA AVAILABLE IN Q1 OF 2021 FOR
ENHANCE-IT STUDY
Source text for Eikon: ID:nGNX1Rtq4q
Further company coverage: MTNB.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Matinas BioPharma Holdings
See all newsBrief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing
Brief: Matinas Biopharma Holdings Inc Keith Kucinski Resigns As CFO Effective January 17, 2026
Brief: Matinas Biopharma Holdings Inc - CFO Keith Kucinski Resigns Effective January 17, 2026 - SEC Filing
Brief: Matinas Biopharma Holdings Eric Ende Resigns As Chairman Of Matinas Biopharma
Brief: Matinas BioPharma Appoints Seasoned Biotech Leaders To Board Of Directors